8-KMaterial Agreements

ABBOTT LABORATORIES 8-K Report, Material Agreement (Oct 22, 2014)

Filed October 22, 2014For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories (ABT) dated October 22, 2014, announces a revision to the Business Transfer Agreement and Plan of Merger with Mylan Inc. The primary update concerns the manufacturing and supply arrangements between Abbott affiliates and New Mylan affiliates post-closing, specifically revising pricing terms for products manufactured by Abbott. Additionally, the number of New Mylan ordinary shares to be issued to Abbott affiliates at closing has been increased to 110,000,000. These modifications signal a recalibration of the financial and operational aspects of the pending transaction between Abbott and Mylan. Investors should note that these changes, while detailed in the filing, are part of a larger, complex transaction with various closing conditions and potential risks. The filing also includes cautionary statements regarding forward-looking information and directs investors to future SEC filings for more comprehensive details on the transaction and its implications.

Key Highlights

  • 1Abbott Laboratories and Mylan Inc. revised their Business Transfer Agreement and Plan of Merger, originally dated July 13, 2014.
  • 2The revision modifies pricing terms for manufacturing and supply arrangements between Abbott affiliates and New Mylan affiliates post-closing.
  • 3The number of New Mylan ordinary shares to be issued to Abbott affiliates at closing has been increased to 110,000,000.
  • 4The filing is considered a communication pursuant to Rule 425 under the Securities Act, related to the proposed transaction.
  • 5Abbott provides cautionary statements regarding forward-looking information and potential risks and uncertainties associated with the transaction.
  • 6Investors are directed to review future SEC filings, including registration statements and proxy statements/prospectuses, for more detailed information about the transaction.

Frequently Asked Questions

This 8-K filing announces revisions to the Business Transfer Agreement and Plan of Merger between Abbott Laboratories and Mylan Inc. Specifically, it updates the pricing terms for post-closing manufacturing and supply agreements and increases the number of New Mylan shares to be issued to Abbott affiliates.

The revision increases the number of New Mylan ordinary shares to be issued to Abbott affiliates at closing from the previously agreed-upon amount to 110,000,000 shares.

The filing outlines several risks, including the potential failure to obtain regulatory approvals, Mylan shareholder approval, satisfaction of closing conditions, material adverse changes affecting either company, unexpected costs or delays, and disruptions to customer, employee, and supplier relationships.

Investors are urged to read the forthcoming registration statement and proxy statement/prospectus to be filed with the SEC, which will contain important information about the transaction. These documents, along with other filings, will be available free of charge on the SEC's website (www.sec.gov).